Silacrown Ether Ion Channels With Controlled Hydrolytic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transmembrane ion channels, particularly those involving crown ethers, suffer from high toxicity and uncontrolled ion flux due to their stable, continuous nature, posing challenges in medical applications related to channelopathies and ion transport.
Innovation Solution
Development of silacrown ethers with controlled hydrolytic stability and exocyclic substituents, such as alkyl groups and peptoids, that form ion channels by self-association or interaction with natural channels, facilitating controlled ion transport across membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crown ethers are used as transmembrane ion channels, then ion transport function is achieved, but toxicity increases and ion flux becomes uncontrolled
Solution Approach 1:
The patent changes the chemical composition parameters by replacing carbon atoms with silicon atoms in the crown ether ring structure. This creates silacrown ethers with different hydrolytic stability properties, allowing controlled ion flux while reducing toxicity. The silicon substitution fundamentally alters the chemical behavior and stability profile of the ion channel.
Solution Approach 2:
The patent creates composite structures by combining silacrown ether rings with various substituent groups (alkyl chains, peptoids, amino acids). These composite molecular structures enable fine-tuning of ion channel properties, providing both controlled ion transport and reduced toxicity through the synergistic effects of different molecular components.
2Stability of the object's composition
If stable crown ether structures are used, then continuous ion flux is achieved, but toxicity increases
Solution Approach 1:
The patent introduces controlled instability by incorporating silicon atoms that undergo hydrolysis at controlled rates. This creates a dynamic stability profile where the ion channel maintains functionality while gradually degrading, reducing long-term toxicity. The hydrolytic stability parameter is precisely tuned through silicon substitution patterns.
3Reliability
If exocyclic substituents are added to silacrown ethers, then ion transport control is improved, but device complexity increases
Solution Approach 1:
The patent segments the ion channel function into distinct molecular components: the silacrown ether ring provides the ion binding site, while exocyclic substituents (alkyl chains, peptoids, amino acids) provide directional control and membrane integration. This modular segmentation allows independent optimization of each functional element.
Solution Approach 2:
The patent applies local quality by placing specific substituent groups at particular positions on the silacrown ether ring. Different regions of the molecule have specialized functions: some substituents provide hydrophobic membrane interaction, others provide directional ion flux control, and others provide stability. This localized functional assignment achieves complex control without requiring overall molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silacrown ethers provide a stable and controlled mechanism for ion transport, reducing toxicity and enhancing the functionality of ion channels in biological systems, addressing channelopathies and improving ion channel performance.
Implementation Method 1
silacrown ethers with controlled hydrolytic stability
Implementation Method 2
form ion channels by self-association or interaction with natural channels
Data Source
AI summary
Silacrown ethers having at least eleven ring atoms and containing at least one substituted or unsubstituted unsaturated hydrocarbon, peptide, or peptoid substituent on the ring and/or on the silicon atom are provided. Azasilacrown ethers having at least eleven ring atoms and containing at least one substituted or unsubstituted, saturated or unsaturated hydrocarbon, peptide, or peptoid substituent on the ring and/or on the silicon atom are also described.